Research analysts at StockNews.com initiated coverage on shares of Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) in a research report issued on Tuesday. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.
HZNP has been the subject of a number of other reports. Piper Sandler cut Horizon Therapeutics Public from an “overweight” rating to a “neutral” rating in a report on Monday, December 12th. SVB Leerink cut shares of Horizon Therapeutics Public from an “outperform” rating to a “market perform” rating and increased their price target for the company from $88.00 to $116.50 in a research note on Tuesday, December 13th. Wells Fargo & Company cut shares of Horizon Therapeutics Public from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $118.00 to $116.50 in a research report on Monday, December 12th. Stifel Nicolaus lowered Horizon Therapeutics Public from a “buy” rating to a “hold” rating and decreased their price objective for the company from $138.00 to $116.50 in a research report on Monday, December 12th. Finally, Guggenheim downgraded Horizon Therapeutics Public from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $98.00 to $116.50 in a research report on Tuesday, December 13th. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $111.42.
Horizon Therapeutics Public Trading Up 0.5 %
Shares of Horizon Therapeutics Public stock opened at $109.30 on Tuesday. Horizon Therapeutics Public has a 12-month low of $57.84 and a 12-month high of $117.49. The stock has a market capitalization of $24.97 billion, a P/E ratio of 49.01, a price-to-earnings-growth ratio of 4.09 and a beta of 1.13. The company has a 50-day simple moving average of $109.47 and a 200 day simple moving average of $96.06. The company has a quick ratio of 3.67, a current ratio of 3.85 and a debt-to-equity ratio of 0.50.
Insider Buying and Selling at Horizon Therapeutics Public
In related news, CFO Aaron Cox sold 36,148 shares of the firm’s stock in a transaction dated Friday, January 13th. The shares were sold at an average price of $113.17, for a total value of $4,090,869.16. Following the completion of the sale, the chief financial officer now directly owns 277 shares in the company, valued at approximately $31,348.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Horizon Therapeutics Public news, CFO Aaron Cox sold 36,148 shares of Horizon Therapeutics Public stock in a transaction on Friday, January 13th. The shares were sold at an average price of $113.17, for a total transaction of $4,090,869.16. Following the completion of the transaction, the chief financial officer now directly owns 277 shares of the company’s stock, valued at $31,348.09. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Andy Pasternak sold 27,129 shares of the company’s stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $113.03, for a total transaction of $3,066,390.87. Following the completion of the transaction, the executive vice president now owns 56,338 shares in the company, valued at $6,367,884.14. The disclosure for this sale can be found here. Company insiders own 2.50% of the company’s stock.
Institutional Investors Weigh In On Horizon Therapeutics Public
A number of institutional investors have recently made changes to their positions in the company. Elequin Securities LLC acquired a new stake in Horizon Therapeutics Public during the 4th quarter worth approximately $25,000. Whittier Trust Co. of Nevada Inc. bought a new stake in shares of Horizon Therapeutics Public in the fourth quarter valued at about $28,000. CoreCap Advisors LLC acquired a new position in shares of Horizon Therapeutics Public in the fourth quarter valued at about $30,000. Allworth Financial LP increased its position in Horizon Therapeutics Public by 936.7% during the third quarter. Allworth Financial LP now owns 622 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 562 shares during the period. Finally, CI Investments Inc. grew its position in shares of Horizon Therapeutics Public by 75.9% during the 3rd quarter. CI Investments Inc. now owns 628 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 271 shares in the last quarter. Institutional investors own 91.01% of the company’s stock.
Horizon Therapeutics Public Company Profile
Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.
Featured Stories
- Get a free copy of the StockNews.com research report on Horizon Therapeutics Public (HZNP)
- This Is Why Penny Stock GreenPower Motor Company Is A Win
- Comcast Sum of All Parts is Producing a Cumulative Effect
- The Greenbrier Companies: All Aboard For High-Yield In 2023
- Coty Stock is on the Comeback Trail
- Is Halliburton Stock a Value or a Value Trap?
Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.
